Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by ACELYRIN, INC. ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024 September 19, 2024 From ACELYRIN, INC. Via GlobeNewswire Tickers SLRN ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive September 10, 2024 From ACELYRIN, INC. Via GlobeNewswire Tickers SLRN ACELYRIN, INC. to Participate in Upcoming Investor Conferences August 22, 2024 From ACELYRIN, INC. Via GlobeNewswire Tickers SLRN ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results August 13, 2024 From ACELYRIN, INC. Via GlobeNewswire Tickers SLRN ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024 August 06, 2024 From ACELYRIN, INC. Via GlobeNewswire Tickers SLRN ACELYRIN, INC. Announces Positive 16-week Data From its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to be Shared During Late-Breaking Oral Presentation at EULAR 2024 June 05, 2024 From ACELYRIN, INC. Via GlobeNewswire Tickers SLRN ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024 May 29, 2024 From ACELYRIN, INC. Via GlobeNewswire Tickers SLRN ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones May 09, 2024 From ACELYRIN, INC. Via GlobeNewswire Tickers SLRN ACELYRIN, INC. Announces Leadership Transition May 09, 2024 From ACELYRIN, INC. Via GlobeNewswire Tickers SLRN ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024 April 29, 2024 From ACELYRIN, INC. Via GlobeNewswire Tickers SLRN ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights March 28, 2024 From ACELYRIN, INC. Via GlobeNewswire Tickers SLRN ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease March 20, 2024 From ACELYRIN, INC. Via GlobeNewswire Tickers SLRN ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis March 11, 2024 From ACELYRIN, INC. Via GlobeNewswire Tickers SLRN ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patients March 11, 2024 From ACELYRIN, INC. Via GlobeNewswire Tickers SLRN ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications February 15, 2024 From ACELYRIN, INC. Via GlobeNewswire Tickers SLRN ACELYRIN, INC. Appoints Lynn Tetrault to Board of Directors December 20, 2023 From ACELYRIN, INC. Via GlobeNewswire Tickers SLRN ACELYRIN, INC. Provides Update on Izokibep Clinical Development Program November 27, 2023 From ACELYRIN, INC. Via GlobeNewswire Tickers SLRN ACELYRIN, INC. Reports Third Quarter 2023 Financial Results and Recent Highlights November 07, 2023 From ACELYRIN, INC. Via GlobeNewswire Tickers SLRN ACELYRIN, INC. Appoints Patricia Turney as Chief Technical Operations Officer November 06, 2023 From Acelyrin, Inc. Via GlobeNewswire Tickers SLRN ACELYRIN, INC. to Report Third Quarter 2023 Financial Results and Corporate Update on November 7, 2023 October 31, 2023 From Acelyrin, Inc. Via GlobeNewswire Tickers SLRN ACELYRIN, INC. Scales for Continued Late-Stage Growth with The Appointment of Dr. Shephard Mpofu as Senior Vice President of Development October 03, 2023 From Acelyrin, Inc. Via GlobeNewswire Tickers SLRN ACELYRIN, INC. Announces Top-Line Results from Placebo-Controlled Clinical Trial of Izokibep for Moderate-to-Severe Hidradenitis Suppurativa September 11, 2023 From Acelyrin, Inc. Via GlobeNewswire Tickers SLRN ACELYRIN, INC. to Present at the Morgan Stanley 21st Annual Global Healthcare Conference September 06, 2023 From Acelyrin, Inc. Via GlobeNewswire Tickers SLRN ACELYRIN, INC. Reports Second Quarter 2023 Financial Results and Recent Highlights August 14, 2023 From Acelyrin, Inc. Via GlobeNewswire Tickers SLRN ACELYRIN, INC. to Present Second Quarter 2023 Financial Results and Corporate Update on August 14, 2023 August 07, 2023 From Acelyrin, Inc. Via GlobeNewswire Tickers SLRN ACELYRIN, INC. Appoints Ken Lock as Chief Commercial Officer July 18, 2023 From Acelyrin, Inc. Via GlobeNewswire Tickers SLRN ACELYRIN, INC. Reports First Quarter 2023 Financial Results and Recent Highlights June 15, 2023 From Acelyrin, Inc. Via GlobeNewswire Tickers SLRN Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.